AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- Imugene has presented data from Phase I CHECKVacc trial on TNBC patients at a symposium in Texas, USA.
- Data from the trial implied safety and tolerance of CF33-hNIS-antiPD-L1 in patients with metastatic TNBC.
Imugene Limited (ASX: IMU) has presented first and new data from Phase I CHECKVacc trial on patients having triple negative breast cancer (TNBC). The ASX-listed clinical stage immuno-oncology firm presented the data as a poster presentation at the 2022 San Antonio Breast Cancer Symposium (SABC 2022) in San Antonio. The symposium was held on 9 December 2022 AEDT.
© 2022 Kalkine Media®, Data and image source: Company update
Data from the trial implied that CF33-hNIS-antiPD-L1 administered by intratumoral injection in patients with metastatic TNBC is safe and well tolerated at the tested dose levels. Below are some focal points of the results:
- The study enrolled six patients who received at least one dose of CHECKvacc injection at dose level 1 (1 x 10^5 pfu) or dose level 2 (3 x 10^5 pfu).
- There were no dose-limiting toxicities and no adverse events related to treatment. However, injection site discoloration was observed in one patient.
- 99mTc SPECT imaging for virus tracking from virus induced replication of the human sodium iodide (hNIS) transgene demonstrated improvement in 4/6 (67%) patients in the first two dose levels. Improvement was higher in patients with nodal disease injection than dermal metastasis.
- SPECT imaging of patient COH-004 (DL-2) on C1D8 demonstrated substantial improvement of the injected lymph node.
- Baseline and on-treatment tumor biopsies of patient COH-004 using spatial immune profiling showed a surge in PD-L1 positive cells following treatment with CHECKVacc. It demonstrated immune activation and tumor microenvironment changes in association with response to therapy.
Read: Imugene (ASX:IMU) doses first patient in VAXINIA intratumoral cohort-2
Overall, data from the trial provide for further evaluation of CHECKVacc in TNBC.
At the time of writing this article, share price of IMU was AU$0.180 apiece.